• 1. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 2. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 3. Distinction of trans–cis photoisomers with comparable optical properties in multiple-state photochromic systems – examining a molecule with three azobenzenes via in situ irradiation NMR spectroscopy?
  Jonas Kind,Lukas Kaltschnee,Martin Leyendecker,Christina M. Thiele Chem. Commun., 2016,52, 12506-12509
• 4. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 5. Fatty acid positional distribution in colostrum and mature milk of women living in Inner Mongolia, North Jiangsu and Guangxi of China?
  Long Deng,Qian Zou,Biao Liu,Wenhui Ye,Chengfei Zhuo,Li Chen,Ze-Yuan Deng,Ya-Wei Fan,Jing Li Food Funct., 2018,9, 4234-4245

Ethyl 7-((4-chloro-7-methoxyquinazolin-6-yl)oxy)heptanoate: A Comprehensive Overview

Ethyl 7-((4-chloro-7-methoxyquinazolin-6-yl)oxy)heptanoate, a compound with the CAS number 1012057-26-9, represents a significant advancement in the field of pharmaceutical chemistry. This compound belongs to a class of molecules that have garnered considerable attention due to their potential applications in drug development and medicinal chemistry. The intricate structure of this molecule, featuring a quinazoline core and an extended heptanoate side chain, makes it a subject of intense study for researchers aiming to develop novel therapeutic agents.

The quinazoline scaffold is well-known for its presence in numerous biologically active compounds, including several FDA-approved drugs. Its structural versatility allows for modifications that can enhance binding affinity and selectivity, making it an attractive scaffold for drug design. In Ethyl 7-((4-chloro-7-methoxyquinazolin-6-yl)oxy)heptanoate, the presence of a 4-chloro substituent and a 7-methoxy group further refines its pharmacological profile. These functional groups are strategically positioned to interact with biological targets, potentially modulating various cellular processes.

The heptanoate side chain in Ethyl 7-((4-chloro-7-methoxyquinazolin-6-yl)oxy)heptanoate adds another layer of complexity to its chemical behavior. This longer aliphatic chain can influence solubility, metabolic stability, and overall bioavailability. Researchers have been exploring the impact of such structural features on the compound's pharmacokinetic properties, aiming to optimize its therapeutic potential. The combination of these structural elements makes Ethyl 7-((4-chloro-7-methoxyquinazolin-6-yl)oxy)heptanoate a promising candidate for further investigation.

Recent studies have highlighted the importance of quinazoline derivatives in the development of anticancer agents. The< strong>4-chloro- and 7-methoxy-substituted quinazoline core in Ethyl 7-((4-chloro-7-methoxyquinazolin-6-yl)oxy)heptanoate aligns with this trend. Research has demonstrated that such modifications can enhance the ability of quinazoline derivatives to inhibit kinases and other enzymes involved in cancer cell proliferation. For instance, studies have shown that quinazoline-based compounds can disrupt microtubule formation and induce apoptosis in cancer cells. These findings underscore the potential of Ethyl 7-((4-chloro-7-methoxyquinazolin-6-yl)oxy)heptanoate as a lead compound for anticancer drug development.

Beyond oncology, Ethyl 7-((4-chloro-7-methoxyquinazolin-6-yl)oxy)heptanoate has shown promise in other therapeutic areas. Its structural features suggest potential applications in the treatment of inflammatory diseases and infectious disorders. The< strong>quinazoline moiety is known to interact with various biological targets, including receptors and enzymes involved in inflammation. By modulating these targets, Ethyl 7-((4-chloro-7-methoxyquinazolin-6-yloxy)heptanoate could potentially reduce inflammation and alleviate symptoms associated with chronic inflammatory conditions.

In addition to its therapeutic potential, Ethyl 7-((4-chloro-7-methoxyquinazolin-6-yloxy)heptanoate has been studied for its role in drug delivery systems. Researchers are exploring ways to incorporate this compound into nanoparticles and other delivery vehicles to enhance drug targeting and bioavailability. These advancements could lead to more effective treatments for a variety of diseases by ensuring that therapeutic agents reach their intended targets more efficiently.

The synthesis of Ethyl 7-((4-chloro-7-methoxyquinazolin-6-yloxy)heptanoate is another area of active research. Chemists have developed various synthetic routes to produce this compound with high yield and purity. These synthetic strategies often involve multi-step reactions that require careful optimization to ensure the best results. The development of efficient synthetic methods is crucial for scaling up production and making this compound more accessible for further research and clinical trials.

The pharmacological evaluation of Ethyl 7-((4-chloro-7-methoxyquinazolin-6-yloxy)heptanoate has revealed several interesting properties. Preclinical studies have shown that this compound exhibits moderate potency against certain cancer cell lines, suggesting its potential as an anticancer agent. Additionally, it has demonstrated anti-inflammatory effects in animal models, indicating its utility in treating inflammatory diseases. These findings provide a strong rationale for conducting further clinical trials to assess its safety and efficacy in humans.

In conclusion, Ethyl 7-((4-chloro-7-methoxyquinazolin-6-yloxy)heptanoate is a multifaceted compound with significant therapeutic potential. Its unique structure, featuring a< strong>quinazoline core and an extended heptanoate side chain, makes it an attractive candidate for drug development. Recent studies have highlighted its promise in treating cancer, inflammation, and other diseases. As research continues to uncover new applications for this compound, it is likely to play an increasingly important role in the field of pharmaceutical chemistry.

• 88350-06-5(Acetic acid, (8-quinolinyloxy)-, dodecyl ester)
• 921929-70-6(Pentanoic acid, 1H-indol-3-yl ester)
• 35500-49-3(8-Quinolinyl octanoate)
• 654082-37-8(Butanoic acid, 4-[[6-(1H-benzimidazol-2-yl)-2-naphthalenyl]oxy]-, ethylester)
• 874271-11-1(Pentanoic acid, 5-(4-quinazolinyloxy)-, ethyl ester)
• 86137-76-0(Octadecanoic acid, 8-quinolinyl ester)
• 874271-09-7(Hexanoic acid, 6-(4-quinazolinyloxy)-, ethyl ester)
• 88350-04-3(Acetic acid, (8-quinolinyloxy)-, octyl ester)
• 878291-82-8(Butanoic acid, 4-(5-quinolinyloxy)-)
• 133950-66-0(3-indoxyl caprylate)